Post by
Indicator on Mar 24, 2011 12:37pm
re Sales Contracts
Correct ... my estimates are based on production capacity, not on current sales contracts, as the plant is still under construction. MDG's new 90,000 sq. ft. plant is being funded in large part by US 21 Million DARPA grant, (an eye opening endorsement in itself).
The current stock price suggests to me that this is still being considered a 'roll of the dice' by some. I take considerable comfort knowing common shareholders are in very good company with our investment ;-) ;-)
Medicago's technology is reported to enjoy considerable advantages in time required to bring vaccines to market. As governments everywhere are perpetually stockpiling vaccines and in need of this added time sensitive production, with remaining good trial results and Medicago's surge production advantages, significant signed sales contracts are the logical outcome once this manufacturing facility is operational.
As I mentioned previously, there are also MOU's signed with several other countries which, I suspect, will step up to the plate and add considerably to the MDG coffers, once this initial plant is operational.